Ask a doctor about a prescription for CLAVERSAL 500 mg GASTRO-RESISTANT TABLETS
Patient Information Leaflet
Claversal 500 mg Gastro-Resistant Tablets
mesalazine
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Leaflet
Claversal contains mesalazine (also known as 5-aminosalicylic acid), which belongs to a group of medications called intestinal anti-inflammatory agents.
Claversal is indicated for the treatment of ulcerative colitis, an inflammatory disease of the intestine.
Do not take Claversal
Warnings and precautions
Consult your doctor before starting to take Claversal
If you experience severe headache or recurrent headache, vision changes, or ringing in the ears, contact your doctor immediately.
In case of appearance of any allergic manifestation (e.g., skin rash, itching) or cramps, abdominal pain, severe headache, and fever during treatment, do not take more tablets and inform your doctor immediately.
Before and during treatment, your doctor may want to perform regular blood and urine tests to check the functioning of your liver, kidneys, blood, and lungs.
Kidney stones may occur with the use of mesalazine. Symptoms include pain in the sides of the abdomen and blood in the urine. Make sure to drink enough liquid during treatment with mesalazine.
Severe skin rashes, such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (TEN), have been observed with mesalazine treatment. Stop taking mesalazine and seek medical attention immediately if you observe any of the symptoms related to these severe skin reactions described in section 4.
Mesalazine may cause a discoloration of the urine to a reddish-brown color after contact with sodium hypochlorite bleach in the toilet water. This is a chemical reaction between mesalazine and bleach and is harmless.
Children and adolescents
Information on safety in the use of this medication in children and adolescents is limited.
Do not administer to children under 5 years of age.
Other medications and Claversal 500 mg Gastro-Resistant Tablets
In general, you can continue treatment with other medications while taking Claversal. However, inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
Claversal may interact with some medications if taken at the same time.
In particular:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
There is limited experience with the use of mesalazine during pregnancy and breastfeeding. The newborn may develop allergic reactions after breastfeeding, such as diarrhea. If the newborn develops diarrhea, breastfeeding should be interrupted.
Mesalazine is not recommended during pregnancy or breastfeeding unless your doctor advises otherwise.
Driving and using machines
No adverse effects of Claversal on the ability to drive or use machines have been reported.
Claversal 500 mg Gastro-Resistant Tablets contain sodium
This medication contains 49 mg of sodium (main component of table salt) per gastro-resistant tablet. This is equivalent to 2.5% of the maximum recommended daily intake of sodium for an adult.
Consult your doctor or pharmacist if you need to take 8 or more gastro-resistant tablets daily for a prolonged period, especially if you have been advised to follow a low-salt diet.
Follow your doctor's instructions for taking this medication exactly. If in doubt, consult your doctor or pharmacist again.
Your doctor will indicate the duration of your treatment with this medication. Do not stop treatment before completing the prescribed course, as symptoms may return if treatment is stopped too soon.
Strictly follow the treatment as instructed by your doctor, both in the acute inflammatory phase and during the maintenance period.
The recommended dose for an adult is:
Claversal 500 mg Gastro-Resistant Tablets should be taken orally.
The gastro-resistant tablets should be taken before meals and swallowed whole, with the help of liquid. They should not be divided, chewed, or crushed.
Use in children and adolescents
Administration of Claversal to children and adolescents under 18 years of age is not recommended due to lack of safety and efficacy data.
Do not administer to children under 5 years of age.
Use in elderly patients
Use of Claversal in elderly patients should be done with caution and limited to those patients with normal renal function.
If you take more Claversal 500 mg Gastro-Resistant Tablets than you should
Consult your doctor if you have taken more than prescribed. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount taken. It is recommended to bring the packaging and leaflet of the medication to the healthcare professional.
If you forget to take Claversal 500 mg Gastro-Resistant Tablets
Do not take a double dose to make up for forgotten doses.
If you stop treatment with Claversal 500 mg Gastro-Resistant Tablets
It is important to take Claversal 500 mg Gastro-Resistant Tablets every day, even when you do not have symptoms of ulcerative colitis. Always complete the prescribed treatment course.
If you have any further questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
All medications can cause allergic reactions, although severe allergic reactions are very rare. If you experience any of these symptoms after using this medication, stop using it and contact your doctor immediately:
If you experience fever or irritation of the throat or mouth, stop using this medication and contact your doctor immediately. These symptoms may be due to a rare decrease in the number of white blood cells in the blood (a condition called agranulocytosis).
Severe side effects:
Stop taking mesalazine and seek medical attention immediately if you experience any of the following symptoms:
The following side effects have also been reported in patients taking mesalazine:
Rare side effects(may affect up to 1 in 1,000 patients)
Very rare side effects(may affect less than 1 in 10,000 patients)
Side effects of unknown frequency(cannot be estimated from available data).
Photosensitivity
More severe reactions have been reported in patients with pre-existing skin conditions, such as atopic dermatitis and atopic eczema.
If these symptoms persist or worsen, consult your doctor.
Reporting side effects:
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
This medication does not require special storage conditions.
Do not use this medication after the expiration date stated on the packaging after EXP. The expiration date is the last day of the month indicated.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and unused medications in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and unused medications. This will help protect the environment.
Composition of Claversal
Appearance of the product and packaging contents
Claversal 500 mg is presented in the form of orange, oblong, gastro-resistant tablets.
Claversal 500 mg is presented in OPA/Al/PVC//Al blisters contained in packages with 100 gastro-resistant tablets.
Marketing authorization holder
Faes Farma, S.A.
Autonomia Etorbidea, 10
48940 Leioa (Bizkaia)
Spain
Manufacturer
Faes Farma, S.A.
Maximo Agirre Kalea, 14
48940 Leioa (Bizkaia)
Spain
O
Faes Farma, S.A.
Parque Científico y Tecnológico de Bizkaia
Ibaizabal Bidea, Edificio 901
48160 Derio (Bizkaia)
Spain
Date of last revision of this leaflet: January 2025
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)http://www.aemps.gob.es/
The average price of CLAVERSAL 500 mg GASTRO-RESISTANT TABLETS in October, 2025 is around 28.01 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CLAVERSAL 500 mg GASTRO-RESISTANT TABLETS – subject to medical assessment and local rules.